KeepHealthCare.ORG – EPS for Sanofi (SNY) Expected At $0.72; Wins Finance Holdings – Ordinary Shares (caym (WINS) Shorts Down By 13.29%
July 12, 2018 – By Rachel Eickhoff
Analysts expect Sanofi (NYSE:SNY) to report $0.72 EPS on July, 30.They anticipate $0.02 EPS change or 2.70% from last quarter’s $0.74 EPS. SNY’s profit would be $1.79 billion giving it 14.63 P/E if the $0.72 EPS is correct. After having $0.79 EPS previously, Sanofi’s analysts see -8.86% EPS growth. The stock increased 1.44% or $0.6 during the last trading session, reaching $42.13. About 753,863 shares traded. Sanofi (NYSE:SNY) has declined 21.93% since July 12, 2017 and is downtrending. It has underperformed by 34.50% the S&P500. Some Historical SNY News: 24/04/2018 – SANOFI HEAD OF GLOBAL R&D ELIAS ZERHOUNI TO RETIRE; COMPANY NAMES JOHN REED TO TAKE OVER ON JULY 1; 16/05/2018 – Sanofi: Phase 3 Trial Evaluating Dupixent Met Primary and Key Secondary Endpoints; 27/04/2018 – SANOFI SAYS TO CONDUCT 1.5 BLN EUR SHARE BUYBACK PROGRAM EXPECTED TO BE COMPLETED IN MID-2019; 18/04/2018 – CFO Moves: Och-Ziff Capital Management, Sanofi; 30/04/2018 – Sanofi, Regeneron: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma; 17/04/2018 – SANOFI SASY.PA – ADVENT WILL SUPPORT ZENTIVA MANAGEMENT TEAM TO INVEST IN COMPANY’S OPERATIONS, PRODUCTION FACILITIES AND R&D PIPELINE; 29/03/2018 – ABLYNX NV ABLX.BR PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018; 12/04/2018 – Healthcare group Sanofi to invest 350 mln euros in Canada vaccine facility; 25/04/2018 – SANOFI SASY.PA – IF APPROVED, PHYSICIANS WILL BE ABLE TO RESERVE VACCINE FOR YOUNG CHILDREN FOR 2019-2020 FLU SEASON; 16/05/2018 – POSITIVE PHASE 3 TRIAL OF DUPIXENT® (DUPILUMAB) IN ADOLESCENTS WITH INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS
Wins Finance Holdings Inc – Ordinary Shares (caym (NASDAQ:WINS) had a decrease of 13.29% in short interest. WINS’s SI was 15,000 shares in July as released by FINRA. Its down 13.29% from 17,300 shares previously. With 500 avg volume, 30 days are for Wins Finance Holdings Inc – Ordinary Shares (caym (NASDAQ:WINS)’s short sellers to cover WINS’s short positions. The SI to Wins Finance Holdings Inc – Ordinary Shares (caym’s float is 0.09%. It closed at $62 lastly. It is down 366.67% since July 12, 2017 and is uptrending. It has outperformed by 354.10% the S&P500. Some Historical WINS News: 27/04/2018 – 1. Certain troubled stocks have recently been violently squeezing just after the publication of a short report. Reports were often a) well researched b) well documented and/or made aggressive cases for c) terminal fundamentals or outright fraud. $LFIN, $WINS, $HMNY and others; 19/04/2018 DJ Wins Finance Holdings Inc, Inst Holders, 1Q 2018 (WINS); 14/05/2018 – U.S. News & World Report’s Branded Content Wins Financial Communications Society Portfolio Award; 18/05/2018 – Wins Finance Holdings Inc. Reports Unaudited Financial Results for the Six Months Ended December 31, 2017; 27/04/2018 – 2. Not surprisingly, the troubled stocks would eventually plunge on their own. But only after wiping out short sellers when they quickly spiked upward by anywhere from 100% to 900% within just weeks. $LFIN, $WINS, $HMNY; 18/05/2018 – WINS FINANCE HOLDINGS INC – UNDERGOING A REVIEW OF RISK CONTROLS FOR COMPANY’S FINANCIAL GUARANTEE BUSINESS AND MAY REDUCE OPERATION OF THIS BUSINESS
More recent Sanofi (NYSE:SNY) news were published by: Seekingalpha.com which released: “Sanofi says CHMP recommends European approval for Cablivi” on June 29, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial” on July 12, 2018. Seekingalpha.com‘s news article titled: “Sanofi transfers infectious disease unit to Evotec” with publication date: June 19, 2018 was also an interesting one.
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $104.98 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It currently has negative earnings. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Among 2 analysts covering Sanofi (NYSE:SNY), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Sanofi had 2 analyst reports since January 23, 2018 according to SRatingsIntel. The firm has “Hold” rating by Bernstein given on Thursday, February 8. The stock of Sanofi (NYSE:SNY) has “Underweight” rating given on Tuesday, January 23 by Barclays Capital.
Wins Finance Holdings Inc., through its subsidiaries, provides financing solutions to small and medium enterprises in the PeopleÂ’s Republic of China. The company has market cap of $1.23 billion. It offers financial guarantee, leasing, and advisory and agency services primarily in Jinzhong City, Shanxi Province and Beijing. It has a 66.74 P/E ratio. The firm is headquartered in Beijing, the PeopleÂ’s Republic of China.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.